Related references
Note: Only part of the references are listed.Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice
Olivier Outteryck et al.
JOURNAL OF NEUROLOGY (2010)
Natalizumab in the treatment of multiple sclerosis
Brandon Brown
Therapeutics and Clinical Risk Management (2010)
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
A. B. Oturai et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
N. Putzki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
The pharmacovigilance program on natalizumab in Italy: 2 years of experience
G. Tedeschi et al.
NEUROLOGICAL SCIENCES (2009)
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
O. Stuve et al.
NEUROLOGY (2009)
GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
A. D. Goodman et al.
NEUROLOGY (2009)
Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns
Eugene O. Major
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy
J. R. Berger
MULTIPLE SCLEROSIS JOURNAL (2008)
Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire
R. H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Natalizumab: a country-based surveillance program
Gian Luigi Mancardi et al.
NEUROLOGICAL SCIENCES (2008)
Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
Karen Yao et al.
PLOS ONE (2008)
The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL
P. A. Calabresi et al.
NEUROLOGY (2007)
Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test
B. A. Parmenter et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales
JC Hobart et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples
A Riazi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
The Multiple Sclerosis Impact Scale (MSIS-29) - A new patient-based outcome measure
J Hobart et al.
BRAIN (2001)
Share Paper
